Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Reduced by RPg Family Wealth Advisory LLC

RPg Family Wealth Advisory LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,826 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. Regeneron Pharmaceuticals makes up approximately 2.0% of RPg Family Wealth Advisory LLC’s portfolio, making the stock its 20th largest position. RPg Family Wealth Advisory LLC’s holdings in Regeneron Pharmaceuticals were worth $6,123,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in REGN. West Paces Advisors Inc. grew its position in Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 23 shares in the last quarter. Stephens Consulting LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $26,000. Sachetta LLC grew its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares in the last quarter. Crewe Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $28,000. Finally, Lynx Investment Advisory purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth about $33,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $1,146.75 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The company has a fifty day simple moving average of $1,128.09 and a 200 day simple moving average of $1,028.93. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The company has a market cap of $126.36 billion, a P/E ratio of 33.88, a P/E/G ratio of 3.97 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business’s revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $8.79 EPS. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the transaction, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Jason Pitofsky sold 487 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,026 shares of company stock valued at $11,498,705. Insiders own 7.48% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Truist Financial reaffirmed a “buy” rating and set a $1,200.00 target price (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. Wells Fargo & Company upped their price objective on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Guggenheim lifted their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. boosted their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Finally, Morgan Stanley cut their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $1,111.30.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.